The ChEMBL-og

The Chemical Biology Services team invites applications for a 3-year ARISE2 Postdoctoral Fellowship – a unique postdoctoral opportunity that combines advanced research training with hands-on experience in developing innovative technologies and methods to enhance scientific services. Why apply? Make an Impact: Collaborate on high-impact projects that will directly shape and improve the scientific services we provide. Tailored to You: Each fellowship project is developed in collaboration with the fellow and the host team – possibly even involving an industry partner – to ensure a project that combines your ideas with the vision of of the host. Prepare for the Future: The ARISE2 Fellowship is designed to prepare fellows for dynamic careers within research infrastructures, providing both technical depth and professional development. If this sounds interesting, please get in touch by the end of August at oboyle@ebi.ac.uk with your CV. Note that we recruit worldwide. Here is...

We are looking for a highly motivated Computational Biologist / Bioinformatician (*) to join the Chemical Biology Resources team at the European Bioinformatics Institute (EMBL-EBI), located on the Wellcome Genome Campus near Cambridge, as part of the Wellcome Trust funded LIGMAP project, a multi-disciplinary collaboration between University College London and EMBL-EBI. LIGMAP is an ambitious multiyear project, led by University College London, to identify the endogenous ligands of the many proteins of unknown function in the proteome using AI-based methods as well as classical machine learning. You will work closely with the PDBe team at EMBL-EBI, as well as leading researchers in structural biology and machine learning at University College London, to deliver the goals of the project. You will develop descriptors to characterise the binding site of proteins in terms of their ability to recognise ligands, and use these to assess druggability of protein binding sites.   This positi...

ChEMBL 37 arrives with nearly three million compounds, a new modality field for capturing targeted protein degraders, and a wave of data quality improvements.    A new field for targeted protein degradation Around 29,000 bioactivity data points have been annotated with     ACTIVITIES.MODALITY  = “Targeted Protein Degradation” , including around 3,000 legacy bioactivities from approximately 1,200 remapped assays. This marks ChEMBL’s first systematic effort to flag TPD data across the database.        Extensive update of literature data Scientific literature remains the backbone of ChEMBL, and ChEMBL 37 brings one of the more substantial literature updates in recent releases. Compared to ChEMBL 36, the literature source gained approximately 79,000 new assays, 270,000 new bioactivity data points, and 52,000 new compound records — pushing the total literature-derived activity count past 9.55 million. Twelve new c...

  ChEMBL extracts data from the core medicinal chemistry literature and therefore reflects ongoing developments in drug discovery. One area currently attracting high interest is targeted protein degradation: compounds that direct disease-causing proteins to the cell’s degradation machinery.  These modalities are both present and rapidly increasing within ChEMBL, providing an important data source for the community.   Targeted Protein Degradation Data in ChEMBL However, new and emerging modalities bring new challenges. Data should be well structured and FAIR, but for newer modalities, controlled vocabularies may not exist or adequately cover the breadth of data being reported. Cu ration effort in this area supports our broader goals towards generating bespoke datasets and improving AI-readiness.  W e recently had the opportunity to attend the first ISCB UK conference where we presented our work towards the capture and annotatio...

The full programme for the  ChEMBL UGM (June 10-11) is now available on our website. If you are interested in registering, you need to be quick as registration closes on 18th May. See you there.

  Dear ChEMBL and SureChEMBL Community, As you know we are dedicated to keeping ChEMBL and SureChEMBL world-class resources for the scientific community, but to do that effectively, we need to hear from you.  To ensure we are consistently meeting your research needs, we are excited to launch our latest ChEMBL User Survey . Why Your Feedback Matters As we plan the next phases and future developments for our platforms, this survey is your opportunity to have a direct impact. By sharing how you interact with our data, you help us understand what works, what doesn't, and what you need next. Your insights will allow us to: Refine the interface: Make navigating and extracting data smoother and more intuitive. Prioritize new features: Focus our development efforts on the tools that will best support your drug discovery and research processes. Evolve with you: Ensure that ChEMBL and SureChEMBL stay in sync with the...